Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Association of depression phenotypes and antidepressant treatment with mortality due to cancer and other causes: a community-based cohort study

  • Vilalta Lacarra, Anna
  • Vilalta-Franch, Joan
  • Serrano-Sarbosa, Domènec
  • Martí Lluch, Ruth
  • Marrugat, Jaume
  • Garre-Olmo, Josep
Fàrmac antidepressiu; Càncer; Síndrome depressiu, Fármaco antidepresivo; Cáncer; Síndrome depresivo, Antidepressant drug; Cancer; Depressive syndrome, Objective: This study aimed to assess the association of somatic depressive symptoms (SDS), cognitive/emotional depressive symptoms (C-EDS), and antidepressant treatment on mortality due to cancer and other causes in a community cohort.Methods: A community-based sample recruited in 1995, 2000, and 2005 aged between 35 and 75 years was examined in two waves and followed for a median of 6.7 years. SDS and C-EDS phenotypes were assessed using the Patient Health Questionnaire-9. Medication used by participants was collected. Deaths and their causes were registered during follow-up. Cox proportional hazard models stratified by sex were performed to determine the association between depressive phenotypes and mortality.Results: The cohort consisted of 5,646 individuals (53.9% women) with a mean age of 64 years (SD = 11.89). During the follow-up, 392 deaths were recorded, of which 27.8% were due to cancer. C-EDS phenotype was associated with an increased risk of cancer mortality in both men (HR = 2.23; 95% CI = 1.11–4.44) and women (HR = 3.69; 95% CI = 1.69–8.09), and SDS was significantly associated with non-cancer mortality in men (HR = 2.16; 95 CI % = 1.46–3.18). Selective serotonin reuptake inhibitors (SSRIs) were significantly associated with both cancer (HR = 2.78; 95% CI = 1.10–6.98) and non-cancer mortality (HR = 2.94; 95% CI = 1.76–4.90) only in the male population.Conclusion: C-EDS phenotype was related to an increased risk of cancer mortality at 6 years. In addition, the use of SSRIs in the male population was associated with cancer and all-cause mortality., Objectiu: aquest estudi pretenia avaluar l'associació de símptomes depressius somàtics (SDS), símptomes depressius cognitius/emocionals (C-EDS) i tractament antidepressiu sobre la mortalitat per càncer i altres causes en una cohort comunitària. Mètodes: una mostra basada en la comunitat reclutada el 1995, 2000 i 2005 d'entre 35 i 75 anys es va examinar en dues onades i es va seguir durant una mitjana de 6,7 anys. Els fenotips SDS i C-EDS es van avaluar mitjançant el Patient Health Questionnaire-9. Es van recollir els medicaments utilitzats pels participants. Durant el seguiment es van registrar les morts i les seves causes. Es van realitzar models de risc proporcional de Cox estratificats per sexe per determinar l'associació entre fenotips depressius i mortalitat. Resultats: La cohort estava formada per 5.646 individus (53,9% dones) amb una edat mitjana de 64 anys (DE = 11,89). Durant el seguiment es van registrar 392 defuncions, de les quals el 27,8% van ser per càncer. El fenotip C-EDS es va associar amb un augment del risc de mortalitat per càncer tant en homes (HR = 2,23; IC 95% = 1,11-4,44) com en dones (HR = 3,69; IC 95% = 1,69-8,09), i el SDS es va associar significativament. amb mortalitat no per càncer en homes (HR = 2,16; IC 95 % = 1,46–3,18). Els inhibidors selectius de la recaptació de serotonina (ISRS) es van associar significativament tant amb el càncer (HR = 2,78; IC 95% = 1,10-6,98) com amb la mortalitat no per càncer (HR = 2,94; IC 95% = 1,76-4,90) només a la població masculina. Conclusió: el fenotip C-EDS es va relacionar amb un augment del risc de mortalitat per càncer als 6 anys. A més, l'ús d'ISRS a la població masculina es va associar amb càncer i mortalitat per totes les causes., This study was supported by the research grant STL006/17/00234 from the Strategic Plan for Health Research and Innovation (PERIS) 2016–2020 of the Department of Health, Government of Catalonia. The funding sources played no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, nor in the preparation, review, or approval of the manuscript.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child

  • Carrera-García, Laura|||0000-0003-4762-7591
  • Natera-De Benito, D.
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Colomer, Jaume
  • Nascimento, A.
  • Saiz, Albert|||0000-0002-5793-8791
  • Dalmau, Josep|||0000-0001-5856-2813
  • Querol, Luis|||0000-0002-4289-8264
  • Armangue, Thais|||0000-0001-6192-6171
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Placental transfer of NMDAR antibodies causes reversible alterations in mice

  • García-Serra, Anna|||0000-0002-9609-2290
  • Radosevic, Marija
  • Pupak, Anika
  • Brito, Verónica|||0000-0002-4137-0708
  • Ríos, José|||0000-0002-0716-8784
  • Aguilar, Esther
  • Maudes, Estibaliz
  • Ariño, Helena|||0000-0003-4036-1671
  • Spatola, Marianna|||0000-0003-2548-0429
  • Mannara, Francesco
  • Pedreño, Marta
  • Joubert, Bastien
  • Ginés, Silvia
  • Planagumà i Valls, Jesús
  • Dalmau, Josep|||0000-0001-5856-2813
To determine whether maternofetal transfer of NMDA receptor (NMDAR) antibodies has pathogenic effects on the fetus and offspring, we developed a model of placental transfer of antibodies. Pregnant C57BL/6J mice were administered via tail vein patients' or controls' immunoglobulin G (IgG) on days 14-16 of gestation, when the placenta is able to transport IgG and the immature fetal blood-brain barrier is less restrictive to IgG crossing. Immunohistochemical and DiOlistic (gene gun delivery of fluorescent dye) staining, confocal microscopy, standardized developmental and behavioral tasks, and hippocampal long-term potentiation were used to determine the antibody effects. In brains of fetuses, patients' IgG, but not controls' IgG, bound to NMDAR, causing a decrease in NMDAR clusters and cortical plate thickness. No increase in neonatal mortality was observed, but offspring exposed in utero to patients' IgG had reduced levels of cell-surface and synaptic NMDAR, increased dendritic arborization, decreased density of mature (mushroom-shaped) spines, microglial activation, and thinning of brain cortical layers II-IV with cellular compaction. These animals also had a delay in innate reflexes and eye opening and during follow-up showed depressive-like behavior, deficits in nest building, poor motor coordination, and impaired social-spatial memory and hippocampal plasticity. Remarkably, all these paradigms progressively improved (becoming similar to those of controls) during follow-up until adulthood. In this model, placental transfer of patients' NMDAR antibodies caused severe but reversible synaptic and neurodevelopmental alterations. Reversible antibody effects may contribute to the infrequent and limited number of complications described in children of patients who develop anti-NMDAR encephalitis during pregnancy.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Association of depression phenotypes and antidepressant treatment with mortality due to cancer and other causes: a community-based cohort study

  • Vilalta Lacarra, Anna
  • Vilalta-Franch, Joan
  • Serrano-Sarbosa, Domènec
  • Martí Lluch, Ruth
  • Marrugat, Jaume
  • Garre-Olmo, Josep
Fàrmac antidepressiu; Càncer; Síndrome depressiu, Fármaco antidepresivo; Cáncer; Síndrome depresivo, Antidepressant drug; Cancer; Depressive syndrome, Objective: This study aimed to assess the association of somatic depressive symptoms (SDS), cognitive/emotional depressive symptoms (C-EDS), and antidepressant treatment on mortality due to cancer and other causes in a community cohort.Methods: A community-based sample recruited in 1995, 2000, and 2005 aged between 35 and 75 years was examined in two waves and followed for a median of 6.7 years. SDS and C-EDS phenotypes were assessed using the Patient Health Questionnaire-9. Medication used by participants was collected. Deaths and their causes were registered during follow-up. Cox proportional hazard models stratified by sex were performed to determine the association between depressive phenotypes and mortality.Results: The cohort consisted of 5,646 individuals (53.9% women) with a mean age of 64 years (SD = 11.89). During the follow-up, 392 deaths were recorded, of which 27.8% were due to cancer. C-EDS phenotype was associated with an increased risk of cancer mortality in both men (HR = 2.23; 95% CI = 1.11–4.44) and women (HR = 3.69; 95% CI = 1.69–8.09), and SDS was significantly associated with non-cancer mortality in men (HR = 2.16; 95 CI % = 1.46–3.18). Selective serotonin reuptake inhibitors (SSRIs) were significantly associated with both cancer (HR = 2.78; 95% CI = 1.10–6.98) and non-cancer mortality (HR = 2.94; 95% CI = 1.76–4.90) only in the male population.Conclusion: C-EDS phenotype was related to an increased risk of cancer mortality at 6 years. In addition, the use of SSRIs in the male population was associated with cancer and all-cause mortality., Objectiu: aquest estudi pretenia avaluar l'associació de símptomes depressius somàtics (SDS), símptomes depressius cognitius/emocionals (C-EDS) i tractament antidepressiu sobre la mortalitat per càncer i altres causes en una cohort comunitària. Mètodes: una mostra basada en la comunitat reclutada el 1995, 2000 i 2005 d'entre 35 i 75 anys es va examinar en dues onades i es va seguir durant una mitjana de 6,7 anys. Els fenotips SDS i C-EDS es van avaluar mitjançant el Patient Health Questionnaire-9. Es van recollir els medicaments utilitzats pels participants. Durant el seguiment es van registrar les morts i les seves causes. Es van realitzar models de risc proporcional de Cox estratificats per sexe per determinar l'associació entre fenotips depressius i mortalitat. Resultats: La cohort estava formada per 5.646 individus (53,9% dones) amb una edat mitjana de 64 anys (DE = 11,89). Durant el seguiment es van registrar 392 defuncions, de les quals el 27,8% van ser per càncer. El fenotip C-EDS es va associar amb un augment del risc de mortalitat per càncer tant en homes (HR = 2,23; IC 95% = 1,11-4,44) com en dones (HR = 3,69; IC 95% = 1,69-8,09), i el SDS es va associar significativament. amb mortalitat no per càncer en homes (HR = 2,16; IC 95 % = 1,46–3,18). Els inhibidors selectius de la recaptació de serotonina (ISRS) es van associar significativament tant amb el càncer (HR = 2,78; IC 95% = 1,10-6,98) com amb la mortalitat no per càncer (HR = 2,94; IC 95% = 1,76-4,90) només a la població masculina. Conclusió: el fenotip C-EDS es va relacionar amb un augment del risc de mortalitat per càncer als 6 anys. A més, l'ús d'ISRS a la població masculina es va associar amb càncer i mortalitat per totes les causes., This study was supported by the research grant STL006/17/00234 from the Strategic Plan for Health Research and Innovation (PERIS) 2016–2020 of the Department of Health, Government of Catalonia. The funding sources played no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, nor in the preparation, review, or approval of the manuscript.